Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Express Scripts
US Department of Justice
Boehringer Ingelheim
Colorcon
Covington
McKinsey
Chinese Patent Office
Citi
Baxter

Generated: December 10, 2018

DrugPatentWatch Database Preview

Sebela Ireland Ltd Company Profile

« Back to Dashboard

What is the competitive landscape for SEBELA IRELAND LTD, and what generic alternatives to SEBELA IRELAND LTD drugs are available?

SEBELA IRELAND LTD has seventeen approved drugs.

There are seven US patents protecting SEBELA IRELAND LTD drugs.

There are seventy-two patent family members on SEBELA IRELAND LTD drugs in thirty-two countries and two supplementary protection certificates in two countries.

Summary for Sebela Ireland Ltd
International Patents:72
US Patents:7
Tradenames:12
Ingredients:10
NDAs:17

Drugs and US Patents for Sebela Ireland Ltd

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Sebela Ireland Ltd TRANDATE labetalol hydrochloride INJECTABLE;INJECTION 019425-001 Dec 31, 1985 DISCN Yes No ➤ Sign Up ➤ Sign Up
Sebela Ireland Ltd LOTRONEX alosetron hydrochloride TABLET;ORAL 021107-001 Feb 9, 2000 AB RX Yes Yes ➤ Sign Up ➤ Sign Up
Sebela Ireland Ltd NAFTIN naftifine hydrochloride CREAM;TOPICAL 019599-001 Feb 29, 1988 DISCN Yes No ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Expired US Patents for Sebela Ireland Ltd

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Sebela Ireland Ltd MOTOFEN atropine sulfate; difenoxin hydrochloride TABLET;ORAL 017744-002 Approved Prior to Jan 1, 1982 3,646,207 ➤ Sign Up
Sebela Ireland Ltd LOTRONEX alosetron hydrochloride TABLET;ORAL 021107-001 Feb 9, 2000 5,360,800 ➤ Sign Up
Sebela Ireland Ltd RIDAURA auranofin CAPSULE;ORAL 018689-001 May 24, 1985 4,225,597 ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Paragraph IV (Patent) Challenges for SEBELA IRELAND LTD drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Capsules 7.5 mg ➤ Subscribe 2014-04-07
➤ Subscribe Tablets 0.5 mg and 1 mg ➤ Subscribe 2010-12-02

Supplementary Protection Certificates for Sebela Ireland Ltd Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C/GB10/012 United Kingdom ➤ Sign Up PRODUCT NAME: A COMBINATION OF ACYCLOVIR AND HYDROCORTISONE; REGISTERED: UK PL18191/0001-0001 20091112
C0038 France ➤ Sign Up PRODUCT NAME: ACYCLOVIR ET HYDROCORTISONE; NAT. REGISTRATION NO/DATE: NL 36 826 20100420; FIRST REGISTRATION: SK - 2108/08467-R 20091026
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Merck
Chubb
Deloitte
Healthtrust
Teva
Cantor Fitzgerald
Chinese Patent Office
Covington
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.